Effects/NNS
of/IN
1/CD
alpha/NN
,/,
25-dihydroxyvitamin/NN
D3/NN
on/IN
the/DT
human/JJ
chronic/JJ
myelogenous/JJ
leukemia/NN
cell/NN
line/NN
RWLeu-4/NN
./.

The/DT
effects/NNS
of/IN
1/CD
alpha/NN
,/,
25-dihydroxyvitamin/NN
D3/NN
(/(
VD3/NN
)/)
on/IN
proliferation/NN
,/,
differentiation/NN
,/,
and/CC
macromolecular/JJ
synthesis/NN
in/IN
the/DT
new/JJ
Philadelphia/NN
chromosome-positive/JJ
chronic/JJ
myelogenous/JJ
leukemia/NN
cell/NN
line/NN
,/,
RWLeu-4/NN
,/,
were/VBD
investigated/VBN
./.
=====
Binding/NN
of/IN
[3H]VD3/NN
was/VBD
saturable/JJ
,/,
with/IN
approximately/RB
2000-3000/CD
sites/cell/NNS
,/,
and/CC
half-maximal/JJ
binding/NN
occurring/VBG
at/IN
0.21-0.33/CD
nM/NN
./.
=====
Treatment/NN
of/IN
RWLeu-4/NN
cells/NNS
with/IN
VD3/NN
induced/VBD
24R-hydroxylase/NN
activity/NN
,/,
a/DT
marker/NN
of/IN
vitamin/NN
D3/NN
responsiveness/NN
in/IN
many/JJ
tissues/NNS
./.
=====
Exposure/NN
of/IN
RWLeu-4/NN
cells/NNS
to/TO
VD3/NN
also/RB
inhibited/VBD
proliferation/NN
and/CC
DNA/NN
synthesis/NN
with/IN
a/DT
50/CD
%/NN
effective/JJ
dose/NN
of/IN
3.5-10/CD
nM/NN
within/IN
72/CD
h/NN
;/:
in/IN
addition/NN
,/,
protein/NN
and/CC
RNA/NN
synthesis/NN
were/VBD
inhibited/VBN
by/IN
VD3/NN
treatment/NN
./.
=====
Exposure/NN
of/IN
RWLeu-4/NN
cells/NNS
to/TO
5/CD
nM/NN
VD3/NN
for/IN
72/CD
h/NN
caused/VBD
50/CD
%/NN
of/IN
the/DT
cells/NNS
to/TO
differentiate/VB
into/IN
macrophage/monocyte/JJ
type/NN
cells/NNS
as/IN
judged/VBN
by/IN
nitroblue/JJ
tetrazolium/NN
staining/NN
and/CC
adherence/NN
to/TO
plastic/NN
./.
=====
Progressive/JJ
expression/NN
of/IN
cell/NN
surface/NN
maturation-specific/JJ
antigens/NNS
of/IN
the/DT
monocyte/macrophage/JJ
lineage/NN
was/VBD
induced/VBN
by/IN
treatment/NN
of/IN
RWLeu-4/NN
cells/NNS
with/IN
VD3/NN
for/IN
24/CD
to/TO
72/CD
h/NN
at/IN
doses/NNS
that/WDT
inhibited/VBD
cellular/JJ
proliferation/NN
./.
=====
c-myc/NN
RNA/NN
,/,
which/WDT
is/VBZ
constitutively/RB
expressed/VBN
in/IN
RWLeu-4/NN
cells/NNS
,/,
increased/VBD
after/IN
0.5/CD
h/NN
of/IN
treatment/NN
with/IN
50/CD
nM/NN
VD3/NN
and/CC
then/RB
rapidly/RB
decreased/VBD
to/TO
barely/RB
detectable/JJ
levels/NNS
after/IN
4/CD
h/NN
of/IN
treatment/NN
./.
=====
Finally/RB
,/,
the/DT
in/FW
vitro/FW
tyrosine/NN
kinase/NN
activity/NN
associated/VBN
with/IN
the/DT
p210bcr-abl/NN
oncogene/NN
product/NN
was/VBD
decreased/VBN
approximately/RB
50/CD
%/NN
by/IN
VD3/NN
treatment/NN
./.
=====
Because/IN
of/IN
the/DT
presence/NN
of/IN
a/DT
functional/JJ
receptor-effector/JJ
system/NN
for/IN
VD3/NN
and/CC
multiple/JJ
biological/JJ
responses/NNS
to/TO
the/DT
hormone/NN
,/,
these/DT
cells/NNS
provide/VBP
a/DT
unique/JJ
model/NN
system/NN
with/IN
which/WDT
to/TO
probe/VB
the/DT
specific/JJ
effects/NNS
of/IN
VD3/NN
on/IN
cell/NN
growth/NN
and/CC
differentiation/NN
in/IN
chronic/JJ
myelogenous/JJ
leukemia/NN
./.